A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors
Recurrent or metastatic solid tumors
18 Years - 99 Years
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jul 2018 by MedImmune, LLC
No locations available
|Experimental: Monotherapy Arm|
Subjects will receive MEDI6383 until disease progression or adverse event.
|Experimental: Combination Arm|
MEDI6383 and MEDI4736
Biological/Vaccine: MEDI6383 and MEDI4736
Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.